Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of Smad4(Dpc4) immunostaining with pattern of disease progression

Journal of Clinical Oncology

Volumn 29, Issue 22, 2011, Pages 3037-3043

  Crane, Christopher H ^a   Varadhachary, Gauri R ^a   Yordy, John S ^a   Staerkel, Gregg A ^a   Javle, Milind M ^a   Safran, Howard ^b   Haque, Waqar ^c   Hobbs, Bridgett D ^a   Krishnan, Sunil ^a   Fleming, Jason B ^a   Das, Prajnan ^a   Lee, Jeffrey E ^a   Abbruzzese, James L ^a   Wolff, Robert A ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Brown University Oncology Group   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; CETUXIMAB; ERLOTINIB; GEMCITABINE; OXALIPLATIN; SMAD4 PROTEIN; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX; SMAD4 PROTEIN, HUMAN; TUMOR MARKER;

ACNE; ADULT; ADVANCED CANCER; AGED; ANAPHYLAXIS; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL PROTOCOL; CORRELATION ANALYSIS; CYTOLOGY; DEHYDRATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSORY NEUROPATHY; SURVIVAL RATE; TREATMENT OUTCOME; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; CLINICAL TRIAL; DISEASE COURSE; DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PATIENT SELECTION; REMISSION; STATISTICAL ANALYSIS;

ACTUARIAL ANALYSIS; ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; PATIENT SELECTION; RADIOTHERAPY, ADJUVANT; REMISSION INDUCTION; RESEARCH DESIGN; SMAD4 PROTEIN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 80051613675     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.8038     Document Type: Article

References (17)

1. Chauffert B, Mornex F, Bonnetain F, et al: Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer: Definitive results of the 2000-2001 FFCD/SFRO study. Ann Oncol 19:1592- 1599, 2008
2. Loehrer P, Powell M, Cardenes H, et al: A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol 26:214s, 2008 (suppl; abstr 4506)
3. Krishnan S, Rana V, Janjan NA, et al: Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 110:47-55, 2007 (Pubitemid 46986417)
4. Huguet F, André T, Hammel P, et al: Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 25:326-331, 2007 (Pubitemid 350003022)
5. Xiong HQ, Rosenberg A, LoBuglio A, et al: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II Trial. J Clin Oncol 22:2610- 2616, 2004
6. Milas L, Fan Z, Andratschke NH, et al: Epidermal growth factor receptor and tumor response to radiation: In vivo preclinical studies. Int J Radiat Oncol Biol Phys 58:966-971, 2004 (Pubitemid 38221157)
7. Bonner JA, Harari PM, Giralt J: Cetuximab prolongs survival in patients with locoregionally advanced aquamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol 23:489s, 2004 (suppl; abstr 5507)
8. Louvet C, Labianca R, Hammel P, et al: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23:3509-3516, 2005
9. Bardeesy N, Cheng KH, Berger JH, et al: Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev 20:3130-3146, 2006 (Pubitemid 44790628)
10. Iacobuzio-Donahue CA, Fu B, Yachida S, et al: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 27:1806-1813, 2009
11. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981 (Pubitemid 11167383)
12. Evans DB, Rich TA, Byrd DR, et al: Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 127:1335-1339, 1992
13. Huguet F, Girard N, Guerche CS, et al: Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: A qualitative systematic review. J Clin Oncol 27:2269-2277, 2009
14. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004 (Pubitemid 38944402)
15. Poplin E, Feng Y, Berlin J, et al: Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:3778-3785, 2009
16. Philip PA, Benedetti J, Corless CL, et al: Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol 28:3605-3610, 2010
17. Kullmann F, Hollerbach S, Dollinger MM, et al: Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: A multicentre phase II study. Br J Cancer 100:1032-1036, 2009